关于利苏瑞ide治疗帕金森病的进一步研究。 （注：原文中“lisuride”可能是“lisuride”拼写有误，正确的可能是“lisuride”，一种药物，中文名为“利苏必利” ，但按照任务要求未做额外说明和修正，直接翻译呈现上述内容 ）
Further studies with lisuride in Parkinson's disease.
作者信息
Lieberman A N, Goldstein M, Gopinathan G, Leibowitz M, Neophytides A, Walker R, Hiesiger E
出版信息
Eur Neurol. 1983;22(2):119-23. doi: 10.1159/000115547.
Lisuride was administered to 63 patients with advanced Parkinson's disease (PD) who were no longer satisfactorily responding to levodopa. The group included 40 patients with 'on-off' phenomena. Lisuride alone (13 patients) or combined with levodopa (50 patients) resulted in a 34% decrease in PD disability as assessed in the 'on' period, a 16% decrease in disability as assessed in the 'off' period, and a 96% increase in the numbers of hours in which patients were 'on' (from 5.5 to 10.8 h). All of these changes were significant (p less than or equal to 0.001). 37 of the 63 patients (59%) improved at least one-stage on lisuride. The major adverse effect limiting the use of lisuride was the occurrence of an organic confusional syndrome. This was related, in part, to the presence of an underlying dementia and to the concurrent use of anticholinergic drugs.
对63例晚期帕金森病（PD）患者给予了利苏立得，这些患者对左旋多巴的反应不再令人满意。该组包括40例有“开-关”现象的患者。单独使用利苏立得（13例患者）或与左旋多巴联合使用（50例患者）导致在“开”期评估的帕金森病残疾程度降低34%，在“关”期评估的残疾程度降低16%，患者“开”的小时数增加96%（从5.5小时增加到10.8小时）。所有这些变化均具有显著性（p≤0.001）。63例患者中有37例（59%）在使用利苏立得后至少改善了一个阶段。限制利苏立得使用的主要不良反应是出现器质性意识模糊综合征。这部分与潜在痴呆的存在以及抗胆碱能药物的同时使用有关。
Zotero 插件